The Growing Role of Bariatric Surgery in the Management of Type 2 Diabetes: Evidences and Open Questions Authors
First Online: 30 June 2011 DOI:
Cite this article as: Busetto, L., Sbraccia, P., Frittitta, L. et al. OBES SURG (2011) 21: 1451. doi:10.1007/s11695-011-0471-5 Abstract
The use of bariatric surgery in the clinical management of type 2 diabetes has been recently endorsed in the clinical practice recommendations released by the most influential diabetologic associations. However, authoritative critic voices about the application of metabolic surgery in type 2 diabetes continue to appear in diabetologic literature. In this review, we will try therefore to understand what the reasons for this apparent dichotomy. In this paper, we revised what we believe are now clear evidences about the role of bariatric surgery in the treatment of type 2 diabetes in patients with morbid obesity: the efficacy of bariatric surgery in metabolic control, the existence of plausible weight-independent metabolic mechanisms at least in some bariatric procedure, and the importance of the early referral to surgery in patients with firm indications. However, we stressed also the lack of clear high-quality long-term data about the effects of bariatric surgery in the prevention of both macro- and micro-vascular hard endpoints in patients with type 2 diabetes. The accrual of these results will be critical to completely clarify the risk/benefit ratio of bariatric surgery in diabetes, as compared to current pharmacologic therapies. This may be particularly important in patients in which data on long-term efficacy are still not completed, such as in patients with lower BMI levels.
Keywords Bariatric surgery Metabolic surgery Type 2 diabetes References
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg. 1995;222:339–50.
MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1:213–20.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.
Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med. 2004;351:2683–93.
Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. A 4-year case-controlled study. Diabetes Care. 2005;28:2703–9.
Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized controlled trial. JAMA. 2008;299:316–23.
Executive Summary: Standards of medical care in diabetes—2009. Diabetes Care 2009;32:S6-12.
Chipkin SR, Goldberg RJ. Obesity surgery and diabetes: does a chance to cut mean a chance to cure? Am J Med. 2009;122:205–6.
Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanism of diabetes remission after gastrointestinal surgery. Endocrinol. 2009;150:2518–25.
Shauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84.
Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulations and glucose metabolism. Ann Surg. 2004;240:236–42.
Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery
hypocaloric diet in glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.
Pattou F, Beraud G, Arnalsteen L, et al. Restoration of β-cell function after bariatric surgery in type 2 diabetics: a prospective controlled study comparing gastric banding and gastric bypass. Obes Surg. 2007;17:1041–3.
le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favour an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.
Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric bypass surgery. N Engl J Med. 2005;353:249–54.
Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.
Furet JP, Kong LC, Tap J. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57.
Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion. Diabetes. 2002;51:144–51.
Dixon JB, Dixon AF, O'Brien P. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Diabet Med. 2003;20:127–34.
Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20:1245–50.
IDF. Bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes. A position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention; 2011.
Schernthaner G, Kopp H-P, Brix JM, et al. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care. 2011;34:S355–60.
Pinkney JH, Johnson AB, Gale EA. The big fat bariatric bandwagon. Diabetologia. 2010;53:1815–22.
Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5.
Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med. 2008;358:2545–59.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med. 2008;358:2560–72.
Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomized control trial. Lancet. 2005;366:1279–89.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Eng J Med. 2009;360:129–39.
Mannucci E, Monami M, Lamanna C, et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19:604–12.
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med. 2003;348:383–93.
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.
Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–9.
Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m
: an integrative review of early studies. Obes Surg. 2010;20:776–90.
Scopinaro N, Adami GF, Papadia FS, et al. The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with mild obesity (BMI 30–35 kg/m2) and simple overweight (BMI 25–30 kg/m2): a prospective controlled study. Obes Surg. 2011;21:880–8.
© Springer Science + Business Media, LLC 2011